Tauriga Assigned Trial Date On November 6, 2017 From United States District Court New Jersey
Published: May 26, 2017
TRENTON, NJ--(Marketwired - May 24, 2017) - Tauriga Sciences Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company"), a company engaged in the building of life sciences businesses and technologies, has today announced that the Trial date has been scheduled for November 6, 2017 concerning its ongoing federal litigation against its predecessor audit firm Cowan Gunteski & Co. P.A. ("Cowan Gunteski").
The Case Name is: "Tauriga Sciences, Inc. v. Cowan, Gunteski & Co. P.A. et al" (Case No. 3:16-cv-06285-PGS-DEA). The case is being tried at the United States District Court of New Jersey ("New Jersey Federal Court") located in Trenton, New Jersey.
In addition, the Pre-Trial Conference has been scheduled for November 2, 2017. The Company is highly confident in the legal merits of its case as well as the evidentiary record. In light of today's event(s), the Company can now disclose that it is finalizing negotiations for a partial Contingency Engagement Agreement with its litigation counsel -- Silverberg & Weiss, PA.
Tauriga's CEO Seth M. Shaw commented, "The Company has worked extremely hard over the past months to progress in this critically important lawsuit. The assignment of this Trial date, during today's legal proceeding in Trenton, is of great importance to the Company and its future prospects. The Company is fully committed to building a successful future for its shareholders and strongly believes that successfully prosecuting this lawsuit is a major first step after all the harm it suffered toward that ultimate goal."
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (OTC PINK: TAUG) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company's previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpractice lawsuit against its predecessor audit firm, for which it's seeking monetary damages in excess of $4,500,000 USD.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation: expectations, expects, anticipates, believes, hopes, beliefs, plans and objectives regarding the development, use and marketability of products as well as the attainment of certain corporate goals and milestones (i.e. SEC Periodic Filings, Filing of Proxies, etc.). Such forward-looking statements are based on present circumstances and on Tauriga's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Tauriga has little or no control. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by Tauriga with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Mr. Seth M. Shaw
Chairman & Chief Executive Officer
cell # (917) 796 9926
fax # (514) 221 3336